harlan waksal md resigns as chairman of the board of sevion therapeutics  business wire harlan waksal md resigns as chairman of the board of sevion therapeutics march    pm eastern standard time san diegobusiness wiresevion therapeutics inc “sevion” or the “company”otcqbsvon a biopharmaceutical company which discovers develops and acquires nextgeneration biologics for the treatment of cancer and immunological diseases today announced that dr harlan waksal md has resigned as chairman of the board of directors of sevion effective march   due to the increased responsibilities and workload that comes with dr waksal’s role as president and chief executive officer at kadmon corporation llc “we greatly appreciate dr waksal’s presence and strong leadership during his tenure on the board and we wish him well in his business pursuits” noted chief executive officer david rector about sevion therapeutics sevion therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics from both internal discovery and acquisition for the treatment of cancer and immunological diseases the company’s product candidates are derived from multiple key proprietary technology platforms cellbased arrayed antibody discovery ultralong antibody scaffolds and chimerasome nanocages sevion has leveraged these technologies to build a pipeline of innovative product candidates for more information please visit seviontherapeuticscom forwardlooking statements certain statements included in this press release are forwardlooking statements within the meaning of the private securities litigation reform act of  actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including but not limited to the company’s ability to continue as a going concern the ability of the company to consummate additional financings the development of the company’s gene and antibody technology the approval of the company’s patent applications the company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the company if at all the successful implementation of the company’s research and development programs and collaborations the success of the companys license agreements the acceptance by the market of the company’s products the timing and success of the company’s preliminary studies preclinical research and clinical trials competition and the timing of projects and trends in future operating performance and the quotation of the company’s common stock on an overthecounter securities market as well as other factors expressed from time to time in the company’s periodic filings with the securities and exchange commission the sec as a result this press release should be read in conjunction with the company’s periodic filings with the sec the forwardlooking statements contained herein are made only as of the date of this press release and the company undertakes no obligation to publicly update such forwardlooking statements to reflect subsequent events or circumstances contacts for investorssevion therapeuticsjames schmidt  contacts for investorssevion therapeuticsjames schmidt  search advanced news search advanced news search log in sign up sam waksal part of the martha stewart insider trading scandal exits kadmon as company files for  million ipo employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       sam waksal part of the martha stewart insider trading scandal exits kadmon as company files for  million ipo tweet   am june   by mark terry biospacecom breaking news staff kadmon corporation headquartered in new york filed on friday with the us securities and exchange commission for an initial public offering ipo to raise  million kadmon with list on the new york stock exchange under the symbol kdmn kadmon focuses on developing products for unmet medical needs its produce pipeline focuses on autoimmune and fibrotic diseases oncology and genetic diseases on june  kadmon announced that its first patient had been dosed in a phase ii clinical trial of kd for idiopathic pulmonary fibrosis ipf ipf is a chronic ultimately fatal disease that causes lung tissue scarring kd is a rhoassociated coiledcoil kinase  rock inhibitor “this study marks kadmon’s entry into the field of fibrosis a disease area where we believe rock inhibition represents a promising new therapeutic approach” ‘said harlan waksal president and chief executive officer of kadmon in a statement “based on our preclinical studies demonstrating the potential antifibrotic effects of kd we believe our drug may have clinical utility in ipf a significant unmet medical need” on april  the company released preclinical data regarding its antipdlil bifunctional fusion protein kd which stimulates longlasting and persistent immunity to tumors the data showed that kd suppressed tumor growth in various in vivo models effectively blocked the pdl pathway and targeted il cytokine activity activating natural killer nk and cd t cells the company also markets ribasphere for hepatitis c infection qsymia for weight loss and tetrabenazine for movement disorders caused by huntington’s disease the s filing also indicated that the company’s founder sam waksal resigned from the company sam waksal’s brother harlan is the head of the company sam waksal is famous or perhaps infamous for being involved in the insider trading case that sent martha stewart to prison along with sam waksal’s own prison sentence the sec barred him from serving as an officer in a public company which is likely why he left kadmon according to the filings sam waksal will receive  million in severance up to  million in various milestone payments and up to  million as part of various development deals   related jobs     principal investigator – frontage labs   product manager  discoverx   associate scientist  dart neuroscience   rd manager i  biorad labs   biostatistician  global blood therapeutics   research associate  epeius biotech   view more jobs basically what happened link httpwwwcnbccommarthastewartordealchangedmesamwaksalhtml was that sam waksal founder and chief executive officer of imclone systems just days before the us food and drug administration fda was to reject its application for cancer drug erbitux in  attempted to unload company stock and told various family members and friends that they should too when news of the rejection was released the shares plummeted in the case of martha stewart she had unloaded imclone shares based on illegally obtained information from her broker stewart served five months in federal prison and some time on house arrest waksal sentenced in  didn’t get out of prison until  a year after eli lilly acquired imclone for  billion erbitux also was approved by the fda in  sam waksal founded kadmon and brought in harlan to act as chief executive officer harlan waksal was also a cofounder of imclone read at biospacecom related news kadmon initiates phase  clinical trial evaluating kd in idiopathic pulmonary fibrosis  biotech stocks for investors who want longterm returns kadmon to present preclinical data demonstrating that its novel immunooncology compound achieves longlasting and persistent antitumor immunity biogen biib loses  billion in market value in one day after failed trial kadmon announces publication of data demonstrating the potential of rock inhibition to treat chronic graftversushost disease could google googs verily be the next theranos kadmon to present preclinical data demonstrating rock signaling as a key regulator of t follicular helper cell function in autoimmune conditions top biotech startups are looking for you at bio  in san francisco kadmon to present preclinical data demonstrating the importance of rock signaling in modulating immune response top alphabet exec defends google googs verily amid criticism please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • kadmon corporation formerly known as kadmon pharmaceuticals   • biotechpharma  ipo filings • biospace news  all • biospace news  by mark terry                 convicted imclone systems boss becomes chief of innovation at kadmon corporation while brother harlan w waksal m d takes ceo post employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       convicted imclone systems lly boss becomes chief of innovation at kadmon corporation while brother harlan w waksal md takes ceo post tweet   pm september   by jessica wilson biospacecom breaking news staff kadmon corporation llc the new york nybased biopharmaceutical company announced yesterday that samuel waksal has stepped down as chief executive officer and will be replaced by harlan waksal his brother who has served on the board since april  samuel waksal will remain with kadmon as chief of innovation science and strategy the waksal brothers have had a long career in the biotech space which included founding imclone systems incorporated now a whollyowned subsidiary of eli lilly and company the career has been marked with scandal however for samuel waksal who was convicted on charges of insider trading and served a fiveyear sentence to put this in context he was involved in the same scandal that put martha stewart in federal prison as part of his  settlement with the us securities exchange commission samuel waksal agreed to a lifetime ban on helming a publicly traded company the change in leadership at kadmon corporation could be a step to prepare the company for an ipo which could not take place with samuel waksal as ceo in the press release announcing the leadership change kadmon stated “while the company is continuing to explore its strategic and financial opportunities including an initial public offering no specific timelines have been set”   related jobs     research associate  regeneron pharma   scientist  assoc manager  regeneron pharma   research associate  regeneron pharma   postdoctoral fellow  pfizer   research associate  bristolmyers squibb   research scientist  gilead sciences   view more jobs despite the coy statement samuel waksal has not been shy about stating his determination for a kadmon ipo in fact yesterday he said in an interview with cnbc that the company plans to file a form s with the sec by the end of  which is a preparatory step in an ipo in addition as early as september  he told bloomberg “we haven’t seen a biotech market like this since  you get these windows you get companies funded you get shareholders that are interested in an approach a strategy a technology a management team and often you really get big winners in the press release harlan waksal expressed his enthusiasm for “building on the foundation of forwardthinking science clinical research and product pipeline including our current clinical candidates envisioned and put together by sam and our management team” kadmon currently offers treatments for liver diseases with a pipeline that includes novel medicines in the areas of oncology immunology and infectious neurodegenerative and ophthalmic diseases the company’s research targets the metabolomics and signaling pathways associated with disease read at biospacecom related news zymeworks announces strategic collaboration with eli lilly and company lly subsidiary imclone systems lly to develop bispecific antibodies using zymeworks azymetric platform aveo oncology aveo terminates cambridge lease agreement to save  million third rock ventures taps alnylam pharmaceuticals alny ceo genzyme corporation genzimclone systems lly vets as venture partners top  hot biopharma regions for growth and expansion circadian technologies limited ciraxs partner imclone systems corporation imcl commences first phase  clinical trial of vegfr antibody imcc exelixis inc exel taps deborah burke as new cfo kadmon corporation initiates phase a portion of kd study in autosomal dominant polycystic kidney disease amneal pharmaceuticals to double size of its sales distribution center kadmon corporation announces the initiation of a phase ba study of kd and trastuzumab in herpositive metastatic breast cancer novo nordisk as nvo to create  jobs at new seattle obesity center please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • imclone systems • kadmon corporation formerly known as kadmon pharmaceuticals   • biotechpharma  personnel • biospace news  all • biospace news  by jessica wilson                 kadmon corporation  wikipedia kadmon corporation from wikipedia the free encyclopedia   redirected from kadmon pharmaceuticals jump to navigation search kadmon corporation llc traded as nyse kdmn industry biotechnology founded  founder samuel d waksal headquarters  east th street new york ny  united states number of locations warrendale pa and brighton ma key people harlan w waksal md chairman and ceo mr konstantin poukalov chief financial officer and executive vice president mr steven n gordon jd esq executive vice president and general counsel products ribisphere number of employees  website kadmoncom kadmon corporation originally kadmon pharmaceuticals is a biopharmaceutical company based in new york city it also has operations in warrendale pa and brighton ma the company was founded in  by samuel d waksal founder and former ceo of imclone systems now fully merged into eli lilly and company waksal had served a federal prison sentence stemming from his fiduciary role as ceo in the  imclone stock trading case when released in  he was barred from serving as an officer for any publicly traded company but kadmon was privately financed in september  amid plans to take the company to an ipo harlan w waksal brother of samuel waksal became president and chief executive officer while samuel waksal remained on with the title chief of innovation science and strategy in early  sam waksal left kadmon and in june the company filed paperwork for its ipo on july   the companys stock began trading on the nyse under the symbol kdmn product acquisitionsedit during waksals leadership of imclone the company was engaged in early stage research projects for  years before filing its first drug application kadmon however immediately began acquiring drugs further advanced  either already marketed in the us or in the later stages of clinical development it acquired the warrendale pabased company three rivers pharmaceuticals and their ribasphere and topotecan products it also signed an agreement with ontario canadabased valeant pharmaceuticals for their hepatitis c drugs ribavirin and taribavirin now kd cancer drugs xl and xl were acquired from exelixis an inhibitor of several protein kinases xl kd entered phase ii clinical trial for certain indications of nonsmall cell lung cancer and in polycystic kidney disease xl is an inhibitor of protein kinases chk and chk and may increase the sensitivity of cancer cells to radiation therapy in an acquisition atypical for a biotechnology company an yearold chinese herbal formula was added to kadmons portfolio phytoceuticas phy kd is a formula of four botanical products that had long been used for the treatment of gastrointestinal distress preclinical studies have shown it to enhance the therapeutic activity of several anticancer agents in  kd was in a phase ii trial in combination with irinotecan in metastatic colon cancer in  the company acquired rights from brighton mabased nano terra inc for their pharmacomer technology research platform and three drug candidates in clinical development these compounds include slx kd an inhibitor to rho kinase  rock with possible potential in fibrotic disease and focal cerebral ischemia slx kd is a triglyceride transfer protein mtp inhibitor being explored for metabolic disorders slx kd is a phosphodiesterase  pde inhibitor a class of drug used in the treatment of erectile dysfunction in  the rights to salirasib kd a ras antagonist in development for cancer therapy were acquired from concordia pharmaceuticals of fort lauderdale fl it also acquired the rights from burlington mabased dyax corp for dx a matrix metalloproteinase mpp tarageted monoclonal antibody intended to inhibit tumor blood vessel formation and metastasis as of december  kadmon was developing a drug for gastric cancer productsedit as of  kadmon produces four drugs approved by the food and drug administration in the united states ribisphere ribavirin usp tablets for the treatment of chronic hepatitis c infergen interferon alfacon injection for the treatment of hepatitis c amphotec amphotericin b an injectable antifungal drug topotecan hydrochloride for injection approved for certain indications of small cell lung cancer and cervical cancer referencesedit  company overview of kadmon holdings llc bloomberg lp retrieved  september    biotechnology company overview of kadmon corporation llc bloombergcom retrieved  december    bartiromo maria sam waksal kadmon pharmaceuticals ceo cnbccom retrieved  december    former imclone chief acquires drug company the new york times  october  retrieved  december     private financing mil form d us securities and exchange commission retrieved  december    kadmon corporation announces the appointment of dr harlan w waksal as president kadmon corporation announcements kadmon corporation retrieved  november    lash alex june   kadmon seeks ipo with unusual terms that benefit waksal debt holders xconomy retrieved september     carroll john june   sam waksal exited kadmon with m severance deal ahead of ipo fiercebiotech retrieved september     sam waksals kadmon holdings shares open below offering price in debut cnbc llc retrieved  september    a b pollack andrew  october  imclone exchief embarks on new biotech venture the new york times retrieved  december    a b fitzpatrick dimond phd patricia tales from the biotech crypt sam waksal is back in business insightintelligence genetic engineering  biotechnology news retrieved  december    company overview of three rivers pharmaceuticals llc bloomberg businessweek bloombergcom retrieved  december    ho solarina  november  valeant kadmon sign deals on hepatitis c drugs thomson reuters retrieved  december    chmielecki juliann pietanza m catherine aftab dana shen ronglai zhao zhiguo chen xi hutchinson katherine viale agnes et al  egfrmutant lung adenocarcinomas treated firstline with the novel egfr inhibitor xl can subsequently retain moderate sensitivity to erlotinib journal of thoracic oncology   – pmc   pmid  doijtobecaee   pietanza m catherine gadgeel shirish m dowlati afshin lynch thomas j salgia ravi rowland kendrith m wertheim michael s price katharine a et al  phase ii study of the multitargeted tyrosine kinase inhibitor xl in patients with non–smallcell lung cancer journal of thoracic oncology   – pmid  doijtobecf   clinical trial number nct for a safety pharmacokinetic and doseescalation study of kd in subjects with autosomal dominant polycystic kidney disease at clinicaltrialsgov  riesterer oliver matsumoto fumihiko wang li pickett jessica molkentine david giri uma milas luka raju uma  a novel chk inhibitor xl increases human cancer cell radiosensitivity through promotion of mitotic catastrophe investigational new drugs   – pmid  dois   liu shwuhuey cheng yungchi  old formula new rx the journey of phy as cancer adjuvant therapy journal of ethnopharmacology   – pmid  doijjep   a phase ii multicenter randomized placebo controlled double blinded clinical study of kd as a modulator of irinotecan chemotherapy in patients with metastatic colorectal cancer clincaltrialsgov us national institutes of health retrieved  august    company overview of nanoterra bloomberg businessweek bloombergcom retrieved  december    kadmon pharmaceuticals and nano terra announce worldwide exclusive licensing agreement for three novel product candidates nanowerkcom retrieved  december    boerma marjan fu qiang wang junru loose david s bartolozzi alessandra ellis james l mcgonigle sharon paradise elsa et al  comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of rho kinase or atorvastatin blood coagulation  fibrinolysis   – pmc   pmid  doimbcbeb   lee j zheng y von bornstadt d wei y balcioglu a daneshmand a yalcin n et al  selective rock inhibition in focal cerebral ischemia ann clin transl neurol   – pmc   pmid  doiacn   kim enoch stewart campbell olivier schueller et al june  a smallmolecule inhibitor of enterocytic microsomal triglyceride transfer protein slx biochemical pharmacodynamic pharmacokinetic and safety profile journal of pharmacology and experimental therapeutics   – pmid  doijpet retrieved  december    leonardi r alemanni m  the management of erectile dysfunction innovations and future perspectives archivio italiano di urologia andrologia   – pmid    mashiachfarkash e rak r eladsfadia g haklai r carmeli s kloog y wolfson hj  computerbased identification of a novel limk inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton oncotarget   – pmc   pmid    kadmon acquires firstinclass ras antagonist from concordia pharmaceuticals biospace inc retrieved  december    novel mmp inhibitor to be developed in multiindication oncology program dyax corporation retrieved  december    devy l huang l naa l yanamandra n pieters h frans n chang e tao q et al  selective inhibition of matrix metalloproteinase blocks tumor growth invasion and angiogenesis cancer research   – pmid  doican   targeted therapy for treatment of advanced gastric cancer qualifying therapeutic discovery project grants for the state of new york us department of the treasury retrieved  december    ribasphere® ribavirin usp tablets and capsules kadmoncom retrieved  december    infergen® interferon alfacon kadmoncom retrieved  december    amphotec amphotericin b injection lipid complex us national library of medicine department of health  human services medicine retrieved  december    topotecan hydrochloride injection powder for solution us national library of medicine us department of health  human services retrieved  december   retrieved from httpsenwikipediaorgwindexphptitlekadmoncorporationoldid categories biotechnology companies of the united statescompanies listed on the new york stock exchangehidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  march  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view harlan waksal  kadmon holdings inc  email kadmoncom login  day free trial harlan waksal kadmon holdings inc ceopresident export  east th street new york ny  email format for kadmoncom direct phone not available type public employees    revenue    million industry biotechhealthcarebiotechdrugs sic code   biological products except diagnostic biography have you been looking for contact information like phone numbers and emails on harlan waksal lead provides data on him which include twitter linkedin url wiki and biography there is also kadmon holdings inc email addresses within the kadmoncom profile so harlan waksals email could be included harlan waksal is part of the kadmon holdings inc which has its main offices in new york ny currently holds the post of ceopresident you can find the company data on lead under the biotechdrugs industry some possible email formats for harlan waksal are hwaksalkadmoncom harlanwaksalkadmoncom harlankadmoncom and harlanwaksalkadmoncom if you sign up for our free trial you will see our emailkadmoncom addresses similar people harlan wahrman  executive harlan wahrman is the current avp analytics strategy you can find harlan wahrmans linkedin profile phone numbers wiki twitter and biography on western  southern financial groups lead profile as well as western  southern financial group email addresses with the westernsoutherncom domain format harlan wahrmans email may or may not be inside the profile western  southern financial group is situated in cincinnati oh you can find their contact information on lead categorized under financial services some possible email formats for harlan wahrman are hwahrmanwesternsoutherncom harlanwahrmanwesternsoutherncom harlanwesternsoutherncom and harlanwahrmanwesternsoutherncom if you sign up for our free trial you will see our emailwesternsoutherncom addresses harlan walker  technology have you been looking for contact information like phone numbers and emails on harlan walker lead provides data on him which include twitter linkedin url wiki and biography there is also chesterfield county public schools email addresses within the mychesterfieldschoolscom profile so harlan walkers email could be included harlan walker is part of the chesterfield county public schools which has its main offices in chesterfield va currently holds the post of lead programmer you can find the company data on lead under the educationtraining industry some possible email formats for harlan walker are hwalkermychesterfieldschoolscom harlanwalkermychesterfieldschoolscom harlanmychesterfieldschoolscom and harlanwalkermychesterfieldschoolscom if you sign up for our free trial you will see our emailmychesterfieldschoolscom addresses harlan walker  executive similar employees madonna rush  executive madonna rush is part of kadmon holdings inc an organization which has its main offices in new york ny madonna serves as the manager systems development at kadmon holdings inc if youre searching for kadmon holdings inc email addresses you can also find those on their lead profile with the domain kadmoncom along with madonna rushs linkedin name twitter tweets wiki phone numbers and biographykadmon holdings incs lead profile is categorized under the biotechdrugs industry some possible email formats for madonna rush are mrushkadmoncom madonnarushkadmoncom madonnakadmoncom and madonnarushkadmoncom if you sign up for our free trial you will see our emailkadmoncom addresses sheila taylor  other kadmon holdings incs senior vice president human resources is where sheila taylor is employed on the other hand the organizations ceo is  they are based in new york ny and you can find their lead profile filed under the biotechdrugs industry sheila taylors profile contains twitter phone numbers linkedin wiki and contact information and you can also find other kadmon holdings inc email addresses on lead with the kadmoncom domain some possible email formats for sheila taylor are staylorkadmoncom sheilataylorkadmoncom sheilakadmoncom and sheilataylorkadmoncom if you sign up for our free trial you will see our emailkadmoncom addresses ed skucas  other located in new york ny kadmon holdings inc has ed skucas serving as the organizations senior scientist ii need ed skucass email linkedin phone numbers facebook wiki and biography you can find essential contact information in kadmon holdings inc lead profile along with their kadmon holdings inc email addresses using the domain search for kadmon holdings inc on lead under the biotechdrugs industry some possible email formats for ed skucas are eskucaskadmoncom edskucaskadmoncom edkadmoncom and edskucaskadmoncom if you sign up for our free trial you will see our emailkadmoncom addresses people directory  harlan waksal ﻿ kadmon corporation announces the appointment of dr harlan w waksal as president and chief executive officer and dr samuel waksal as chief of innovation science and strategy  kadmon holdings inc thank you thank you for visiting wwwkadmoncom  you will now be redirected to an external website disclaimer the website you have selected is an external one and you will now be leaving wwwkadmoncom  kadmon has no responsibility for any external websites  we neither endorse the information content presentation or accuracy nor make any warranty express or implied regarding any external websites continue to leave kadmoncom continue cancel loading press back to index kadmon corporation announces the appointment of dr harlan w waksal as president and chief executive officer and dr samuel waksal as chief of innovation science and strategy new york september   – kadmon corporation llc announces today that harlan w waksal md has joined the company as its president and chief executive officer after serving as a member of the company’s board of managers since april  dr harlan waksal replaces samuel d waksal phd one of the founders of kadmon in the chief executive role dr samuel waksal remains with the company as chief of innovation science and strategy dr harlan waksal brings over  years of executive and governance leadership in the life sciences to kadmon a tenure which includes the cofounding with dr samuel waksal of imclone systems incorporated now a whollyowned subsidiary of eli lilly and company “i look forward to continuing my work with kadmon in my new role as president and chief executive officer and building on the foundation of forwardthinking science clinical research and product pipeline including our current clinical candidates envisioned and put together by sam and our management team” said dr harlan waksal “as we look to the future it is my goal to ensure that the company is wellpositioned to take advantage of valuebuilding corporate strategic and financial options” dr samuel waksal remains with the company as chief of innovation science and strategy and is now responsible for oversight of kadmon’s clinical development research treatment innovation and scientific strategies “i look forward to continuing kadmon’s scientific and clinical work in my new role and to pioneering new medicines addressing areas of serious unmet medical need” said dr samuel waksal while the company is continuing to explore its strategic and financial opportunities including an initial public offering no specific timelines have been set dr samuel waksal remains chairman of the company and will transition from that role in the event that the company elects to pursue an initial public offering   about kadmon corporation kadmon corporation llc is a global company built on a stcentury paradigm for the translation of innovative science into treatment the company currently offers products and services for the treatment and management of liver diseases and is pioneering novel medicines in areas of serious disease including oncology immunology and infectious neurodegenerative and ophthalmic diseases emphasizing emerging concepts in molecular biology and genomics kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease with the goal of addressing some of today’s most pressing areas of unmet medical need for more information visit wwwkadmoncom this press release contains forwardlooking statements these forwardlooking statements are based on management’s expectations and are subject to certain factors risks and uncertainties that may cause actual results outcome of events timing and performance to differ materially from those expressed or implied by such statements no assurance can be given that an initial public offering or other liquidity event will be consummated the information contained in this press release is believed to be current as of the date of original issue kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forwardlooking statements contained herein to reflect any change in our expectations with regard thereto or any change in events conditions or circumstances on which any such statements are based contact information david pitts argot partners  davidargotpartnerscom september   share download microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft forbes welcomeclose more options quote of the day nothing is invented for it’s written in nature first antoni gaudí architect ﻿ leadership team  kadmon holdings inc thank you thank you for visiting wwwkadmoncom  you will now be redirected to an external website disclaimer the website you have selected is an external one and you will now be leaving wwwkadmoncom  kadmon has no responsibility for any external websites  we neither endorse the information content presentation or accuracy nor make any warranty express or implied regarding any external websites continue to leave kadmoncom continue cancel loading leadership team harlan w waksal md president and chief executive officer dr waksal has been our president and chief executive officer since august  and was elected to our board of directors in  prior to joining kadmon as an employee dr waksal served as president and sole proprietor of waksal consulting llc from  to  from  to  dr waksal served as executive vice president business and scientific affairs at acasti pharma inc a publicly traded biopharmaceutical company and as a consultant to neptune technologies  bioressources inc a publicly traded life sciences company and the parent company of acasti dr waksal cofounded imclone systems imclone in  a publicly traded biopharmaceutical company acquired by eli lilly and company in  dr waksal served in senior roles at imclone including president  to  executive vice president and chief operating officer  to  and president chief executive officer and chief operating officer  to  dr waksal also served as a director of imclone from  to  dr waksal served on the boards of oberlin college and sevion therapeutics through march  and the boards of acasti and neptune through february  and july  respectively dr waksal received his ba from oberlin college and his md from tufts university school of medicine he completed his training in internal medicine at new england medical center and in pathology at kings county hospital center in brooklyn konstantin poukalov executive vice president chief financial officer mr poukalov has been our executive vice president chief financial officer since  from  to  mr poukalov served as our vice president strategic operations prior to joining kadmon mr poukalov was a member of the healthcare investment banking group at jefferies llc from  to  focusing on companies across the life sciences and biotechnology sectors prior to jefferies mr poukalov was a member of ubs investment bank focusing on the healthcare industry from  to  mr poukalov serves on the advisory board of pencils of promise a nonprofit organization that aims to increase access to quality education in the developing world mr poukalov received his be from stony brook university lawrence k cohen phd executive vice president research and business development dr cohen has been our executive vice president research and business development since  from  to  dr cohen served as our senior vice president business development prior to joining kadmon dr cohen served as president and chief executive officer of via pharmaceuticals inc a publicly traded biotechnology company from  to  prior to joining via dr cohen served in senior roles including president and chief executive officer at zyomyx inc a privately held diagnostics company from  to  prior to zyomyx dr cohen served as chief operating officer of progenitor inc from  to  dr cohen also served as vice president of research and development at somatix therapy corporation a publicly traded gene therapy company from  to  dr cohen received his ba from grinnell college and his phd from the university of illinois he completed his postdoctoral work in molecular biology at the danafarber cancer institute and the department of biochemistry at harvard medical school steven n gordon esq executive vice president general counsel chief administrative compliance and legal officer mr gordon a cofounder of our company has been our executive vice president general counsel chief administrative compliance and legal officer since  prior to joining kadmon mr gordon worked as a prosecutor for the city of new york from  to  from  to  mr gordon practiced law at several law firms and was the principal of his own law firm mr gordon received his ba from bar ilan university and his jd from touro college jacob d fuchsberg law center john ryan phd md executive vice president chief medical officer dr ryan has been our executive vice president chief medical officer since  prior to joining kadmon dr ryan served as senior vice president and chief medical officer of cerulean pharma inc a publicly traded pharmaceutical company from  to  prior to joining cerulean dr ryan was chief medical officer at aveo pharmaceuticals inc a publicly traded company from  to  prior to joining aveo dr ryan served as senior vice president of translational research at wyeth a publiclytraded specialtypharmaceutical company formerly genetics institute where he served as head of the department of experimental medicine from  to  dr ryan also served as an executive director of clinical research at merck research laboratories from  to  and he previously served on the scientific advisory boards of arqule inc and expression analysis inc dr ryan received his bs and his phd from yale university dr ryan received his md from the university of california san diego find our press releases publications and events read more learn more about our novel drug candidates see our pipeline ﻿ leadership team  kadmon holdings inc thank you thank you for visiting wwwkadmoncom  you will now be redirected to an external website disclaimer the website you have selected is an external one and you will now be leaving wwwkadmoncom  kadmon has no responsibility for any external websites  we neither endorse the information content presentation or accuracy nor make any warranty express or implied regarding any external websites continue to leave kadmoncom continue cancel loading leadership team harlan w waksal md president and chief executive officer dr waksal has been our president and chief executive officer since august  and was elected to our board of directors in  prior to joining kadmon as an employee dr waksal served as president and sole proprietor of waksal consulting llc from  to  from  to  dr waksal served as executive vice president business and scientific affairs at acasti pharma inc a publicly traded biopharmaceutical company and as a consultant to neptune technologies  bioressources inc a publicly traded life sciences company and the parent company of acasti dr waksal cofounded imclone systems imclone in  a publicly traded biopharmaceutical company acquired by eli lilly and company in  dr waksal served in senior roles at imclone including president  to  executive vice president and chief operating officer  to  and president chief executive officer and chief operating officer  to  dr waksal also served as a director of imclone from  to  dr waksal served on the boards of oberlin college and sevion therapeutics through march  and the boards of acasti and neptune through february  and july  respectively dr waksal received his ba from oberlin college and his md from tufts university school of medicine he completed his training in internal medicine at new england medical center and in pathology at kings county hospital center in brooklyn konstantin poukalov executive vice president chief financial officer mr poukalov has been our executive vice president chief financial officer since  from  to  mr poukalov served as our vice president strategic operations prior to joining kadmon mr poukalov was a member of the healthcare investment banking group at jefferies llc from  to  focusing on companies across the life sciences and biotechnology sectors prior to jefferies mr poukalov was a member of ubs investment bank focusing on the healthcare industry from  to  mr poukalov serves on the advisory board of pencils of promise a nonprofit organization that aims to increase access to quality education in the developing world mr poukalov received his be from stony brook university lawrence k cohen phd executive vice president research and business development dr cohen has been our executive vice president research and business development since  from  to  dr cohen served as our senior vice president business development prior to joining kadmon dr cohen served as president and chief executive officer of via pharmaceuticals inc a publicly traded biotechnology company from  to  prior to joining via dr cohen served in senior roles including president and chief executive officer at zyomyx inc a privately held diagnostics company from  to  prior to zyomyx dr cohen served as chief operating officer of progenitor inc from  to  dr cohen also served as vice president of research and development at somatix therapy corporation a publicly traded gene therapy company from  to  dr cohen received his ba from grinnell college and his phd from the university of illinois he completed his postdoctoral work in molecular biology at the danafarber cancer institute and the department of biochemistry at harvard medical school steven n gordon esq executive vice president general counsel chief administrative compliance and legal officer mr gordon a cofounder of our company has been our executive vice president general counsel chief administrative compliance and legal officer since  prior to joining kadmon mr gordon worked as a prosecutor for the city of new york from  to  from  to  mr gordon practiced law at several law firms and was the principal of his own law firm mr gordon received his ba from bar ilan university and his jd from touro college jacob d fuchsberg law center john ryan phd md executive vice president chief medical officer dr ryan has been our executive vice president chief medical officer since  prior to joining kadmon dr ryan served as senior vice president and chief medical officer of cerulean pharma inc a publicly traded pharmaceutical company from  to  prior to joining cerulean dr ryan was chief medical officer at aveo pharmaceuticals inc a publicly traded company from  to  prior to joining aveo dr ryan served as senior vice president of translational research at wyeth a publiclytraded specialtypharmaceutical company formerly genetics institute where he served as head of the department of experimental medicine from  to  dr ryan also served as an executive director of clinical research at merck research laboratories from  to  and he previously served on the scientific advisory boards of arqule inc and expression analysis inc dr ryan received his bs and his phd from yale university dr ryan received his md from the university of california san diego find our press releases publications and events read more learn more about our novel drug candidates see our pipeline harlan waksal md in jupiter fl import  export history plans limited plus premium limitedmonitor your competitors data access data on us ocean freight imports from the last  months for all companies youll have access to data from the previous months from the date of your search we use a rolling date range so you can always look back  months from the current date limitedmonitor your competitors data access data on us ocean freight imports from the last  months for all companies access data on us ocean freight imports from the last  months for all companies youll have access to data from the previous months from the date of your search we use a rolling date range so you can always look back months from the current date plussmall  medium business data access data on us ocean freight imports from the last  months for all companies youll have access to data from the previous months from the date of your search we use a rolling date range so you can always look back months from the current date us ocean freight exports from january   to present for all companies premium empire builder data access data on us ocean freight imports from november  to the present for all companies youll have access to our entire database of shipping manifests of us ocean freight imports going back to november  us ocean freight exports from january   to present for all companies limitedmonitor your competitors usage track the shipping activities of your  chosen companies our limited plan lets you monitor the shipping activities of any three companies across all our databases be the first to know when your target company clears a shipment through customs in one of the countries we track  contact info requests per month our team of account managers and research assistants will help you find contact information for up to  companies in our database each month download csv and xls k records per month if youre planning to do more indepth research on the companies in our database you should upgrade to the plus or premium plans which allow more downloads email alerts for up to  searches if you need to track more than  companies product segments or trade lanes you should upgrade to the plus or premium plan which allow more email alerts limitedmonitor your competitors usage  company searches per day  searches per day may be enough if you are just monitoring a few competitors or researching suppliers in a single industry if youre looking to connect with sales leads or do more indepth research you should upgrade to the plus or premium plan which allows more searches  contact info requests per month our team of account managers and research assistants will help you find contact information for up to  companies in our database each month download csv and xls k records per month if youre planning to do more indepth research on the companies in our database you should upgrade to the plus or premium plan which allow more downloads email alerts for up to  company searches if you need to track more than  companies product segments or trade lanes you should upgrade to the plus or premium plan which allow more email alerts plus small  medium business usage  searches per day  searches per day may be enough if you are just monitoring a few competitors or researching suppliers in a single industry if youre looking to connect with sales leads or do more indepth research you should upgrade to the premium plan which allows more searches  contact info requests per month our team of account managers and research assistants will help you find contact information for up to  companies in our database each month download csv and xls k records per month if youre planning to do more indepth research on the companies in our database you should upgrade to the premium plan which allow more downloads email alerts for up to  searches if you need to track more than  companies product segments or trade lanes you should upgrade to the premium plan which allow more email alerts premium empire builder usage  searches per day    contact info requests per month our team of account managers and research assistants will help you find contact information for up to  companies in our database each month download csv and xls k records per month if youre planning to do more indepth research on the companies in our database contact the sales department to purchase more credits and export additional shipping records email alerts for up to  searches plus small  medium business features visual mapping our visual mapping technology provides an instant snapshot of any companys trade connections navigate the global web of trading partners with the click of a mouse and visualize the relationships between companies many degrees apart premium empire builder features visual mapping our visual mapping technology provides an instant snapshot of any companys trade connections navigate the global web of trading partners with the click of a mouse and visualize the relationships between companies many degrees apart limited monitor your competitors support our customer service agents are available when you need them call in to receive helpful tips and training call or email our customer service agents they will get back to as soon as possible to assist you with your data needs plus small  medium business support our customer service agents are available when you need them call in to receive helpful tips and training call or email our customer service agents they will get back to as soon as possible to assist you with your data needs premium empire builder support our customer service agents are available when you need them call in to receive helpful tips and training call or email our customer service agents they will get back to as soon as possible to assist you with your data needs dedicated research assistant an experienced trade data specialist will serve as your dedicated account manager to locate hardtoreach data perform searches and compile reports on your behalf limited monitor your competitors data access data on us ocean freight imports from the last  months for all companies youll have access to data from the previous months from the date of your search we use a rolling date range so you can always look back  months from the current date x home how it works us data additional countries our datasets our clients ig reviews videos pictures presentation plans  pricing search contact us live chat free demo sign in join now english  french english  french get global shipment alerts for harlan waksal md  month processing please wait  cardholders name tell us your full name credit card no enter a valid card no exp date  january  february  march  april  may  june  july  august  september  october  november  december           postal code  zip or postal code if not in the usa terms of service submit service   sales  live chat choose language english  french hi may i help you with something an importgeniuscom sales agent is available to answer your question chat live now no thanks sign up home how it works plans  pricing search contact us live chat  harlan waksal md harlan waksalmd imports from periwal exports in india through the port of new york new york call     import genius our bill of lading data reveals the trading activities of harlan waksal md and millions of other importers learn more join now request a demo would you like to schedule a free demo wed love to show you international trade data relevant to your own business name email phone schedule a free demo play muted international trade starts with our data other companies in our database starbucks coffee seattle toys rus warehouse  shin caterpillar mitsubishi sears merchandising services inc lululemon usa inc view sample shipment records shipment alert subscription contact this company sign up sample shipment record for harlan waksal md harlan waksalmd imports from periwal exports in india through the port of new york new york bill of lading manufacturer  shipper consignee periwal exports periwal farms araji no   part  to  badi hawal udaipur raj in harlan waksalmd  schooner lane jupiter florida  us notify party marks and numbers box no box no master bill of lading number container number nyks nyku nyku product description indian artistic handicraft itemsmade of woodother than antiqueand banned itemswc ganesh wc pot with inlay workwc fruit platewc flower basketwc candle standwc box with inlay work indian artistic handicraft itemsmade of woodother than antiqueand banned itemswc ganesh wc pot with inlay workwc fruit platewc flower basketwc candle standwc box with inlay work bill of ladingswgbnsamiaarrival dateweight lbweight kgquantity cascontainer countvoyage nowport of loadingnhava shevaport of dischargenew york new yorkvessel namecma cgm eiffelcarrier codeswgbcountry of originindiaplace of receiptmumbai subscribe to access the complete shipping history for harlan waksal md join now how will your business use our trade data if youre involved in international trade our database of shipping manifests will help you find opportunities to grow your business find trading partners you can trust monitor competitors shipping activities connect with sales prospects very informative and great site and so quick pretty slick betty fatzie president lab products inc the service was great with a reasonable price and great results we have now started using another supplier from china we just ordered our first container from the new supplier and with the savings it more than paid for the importgeniuscom service on the first container load cleve kurz gifford monument works import genius is not merely an investment for our organization it’s a vital instrument to effectively manage our time it has afforded us the ability to quickly segment target and position ourselves in front of prospective clients thank you import genius david bryant director of business development john s james co import genius data is fantastic for evaluating component manufacturers in china sanjay dastoor boostedboardscom we have confidence that were working with the best manufacturers in part because import genius showed us that they already supply some of the worlds top brands yaniv masjedi vice president nextivacom import genius is a highly informative tool for monitoring public companies operating activities it is an invaluable part of our research eric delamarter managing partner half moon capital we find new clients for our customs brokerage in the importgenius database almost every day jayson gispan customs brokerage operations manager flexportcom importgenius is a great research tool we use it to evaluate manufacturers to make sure we are working with only the highest quality most reliable suppliers chris friedland founder  ceo buildcom importgenius gave us visibility into the actual shipping histories of the manufacturers we were evaluating and helped us feel comfortable we were working with the best suppliers in china morena simitic coo bellabeatcom shipment alert subscription get email alerts when harlan waksal md has new shipments processing please wait  submit contact harlan waksal md name business email phone submit processing please wait    features save and share reports easily get your searches out of import genius and into your team’s hands for further analysis export your findings to xls or csv or send reports via email it’s the simple things that make our trade data even more valuable to you see the supply chain visual mapping shows you exactly how your target companies and their trading partners connect search by shipper and see everyone they’ve shipped to or search by consignee and see all their suppliers zoom in on any company to see their own trading network dive deep into international trade and discover the links in anyone’s supply chain get realtime shipment alerts stay on top of your competitors suppliers and customers with realtime alerts just set up a search and get an email whenever a new shipment matches your terms import genius lets you know the moment they bring in a rival product or start shipping to a new partner harlan waksal md youve viewed  profile pages on import genius which is the most we allow for free sign up for importgenius to get more details on over  million importers and exporters it only takes seconds sign up for import genius plans limited monitor your competitors recommended plan plus small  medium business premium empire builder price    month for  months sign up    month for  months sign up    month for  months sign up data access data on us ocean freight imports from the last  months for all companies view details access data on us ocean freight imports from the last  months for all companies us ocean freight exports from january   to present for all companies view details access data on us ocean freight imports from november  to the present for all companies us ocean freight exports from january   to present for all companies view details usage track the shipping activities of your  chosen companies  contact info requests per month download csv and xls k records per month email alerts for up to  searches view details  searches per day  contact info requests per month download csv and xls k records per month email alerts for up to  searches view details  searches per day  contact info requests per month download csv and xls k records per month email alerts for up to  searches view details features   visual mapping view details visual mapping view details support our customer service agents are available when you need them call in to receive helpful tips and training view details our customer service agents are available when you need them call in to receive helpful tips and training view details our customer service agents are available when you need them call in to receive helpful tips and training dedicated research assistant view details view all us imports instantly search  ocean freight records to monitor us importers research suppliers generate sales leads and more as featured in what is import genius who uses import genius available data fields what is import genius import genius reveals the trading activities of importers and exporters around the world we give you hard data about your overseas suppliers and domestic competitors using shipping databases from customs agencies in the united states latin america and india import genius can help you find reliable new trading partners monitor your competitors’ shipments and keep an eye on your current suppliers and customers our team of seasoned importexport veterans cuttingedge software developers and customer service professionals has worked for years to build the worlds most powerful and accessible database of international trade intelligence we do this for a diverse client base that requires keen insight into international trade our customers include some of the worlds top importers exporters freight forwarders logistics companies manufacturers investment banks financial analysts intellectual property attorneys and more they use our tools to research the trade activity of importers and suppliers identify and vet new sources for any kind of product monitor the competition and their trade connections generate sales leads for transportation and logistics companies track the activity of publiclytraded companies investigate and enforce intellectual property infringement ensure exclusive agent compliance who uses import genius sourcing professionals use our service to view shipping histories for suppliers we provide access to detailed customs records letting you verify suppliers true shipping volumes and us customer lists you can also look up your competing import firms to find where they buy their goods  learn more competitive intelligence analysts use our service to learn where rivals source products we give clear insights into the importing volumes new product releases and broader competitive dynamics of your industry  learn more sales  marketing teams use our service to generate sales prospects we give you the tools to target importers based on product type location shipping volumes and more  learn more financial analysts use our service to monitor public companies imports we offer rare data on the success or failure of new product launches shipping trends and other operating data for companies in any industry  learn more available data fields import genius data fields by collecting the ocean freight bill of lading for all us imports in our database import genius provides unprecedented access to near realtime information on virtually every industry and company importing goods into the country for each shipment entering the us by ocean we provide access to the following information additional fields available for some shipments phone number fax number email contact person list of data fields consigneethe company importing the shipment into the usconsignee addressthe address of the company importing the shipment into the usshipperthe overseas company exporting the shipment to the usshipper addressthe address of the overseas company exporting the shipment to the usproduct descriptionthe exporters description of the shipment as it appears on the bill of lading or shipping manifestgross weightthe gross weight of the shipment excluding the weight of the actual container this can appear in either pounds or kilograms at the discretion of the exporternumber of unitsthe quantity of boxes customs would find if they were to open the shipment for inspectionvolumethe volume of the shipment generally defined in cubic meters or container base measurements cbmarrival datethe date the shipment arrives within the customs territory of the usforeign portthe last port the shipment passes through before arriving in the uscountry of originthe country of the last foreign port the shipment passes through before arriving in the usus portthe us port where the shipment enters the customs territory of the uscarrier codethe four digit standard carrier alpha code of the ocean carrier or freight forwarder managing the transit of the shipmentvoyage numbera unique code assigned to that particular sailing of the ship between two portsvessel namethe name of the ship transporting the shipmentship registered inthe country where the ship is officially registeredbill of lading numberthe unique number assigned to this particular shipment by the ocean carrier or freight forwardercontainer numberthe unique number assigned to the ocean shipping container carrying the shipment in questionmarks  numbersany text or numbers appearing on the cartons import genius how it works plans  pricing our trade data blog search latin trade data import genius reviews  press coverage who uses import genius contact us latest posts trump properties have… india us palm oil imports… chilean salmon exports… limited plan now available solar panels imports… company profiles paul palermo president sws imports walter gembh top union industry  trading co l atege gmbh as agents shanghai hui en international co lt    records in our database and counting customer support team tel  international   fax   infoimportgeniuscom  e pima center pkwy suite  scottsdale az  shanghai china tel  mobile no  fax number  shenzhen china tel  mob  fax  have questions well reply quickly type your info below message submit processing please wait    trainings demos and general contact all available or call us service  sales  back to top all rights reserved copyright   trade data services inc  were offline please leave us a message to chat with a representative of import genius your browser needs to be internet explorer  or higher please fill out the form below and a representative will contact you as soon as possible name email phone message send x